We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Molecular Diagnostics Market to Reach USD 11 Billion by 2023

By LabMedica International staff writers
Posted on 31 May 2018
The global molecular diagnostics market is expected to grow at a CAGR of 8.4% from USD 7.71 billion in 2018 to USD 11.54 billion by 2023, driven by the increasing prevalence of infectious diseases and various types of cancers, rising awareness and acceptance of personalized medicine and companion diagnostics, growth of the biomarker identification market, and advancements in molecular techniques.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a global market research company.

Based on technology, the PCR segment is expected to account for the largest share of the molecular diagnostics market in 2018 due to the increasing use of PCR in proteomics and genomics, automation of PCR instruments, and emergence of advanced technologies such as qRT-PCR.

On the basis application, the molecular diagnostics market is expected to be dominated by the infectious diseases segment in 2018, owing to the development of advanced assays for various diseases and conditions, sharp rise in the prevalence of infectious diseases, and growing awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases.

Based on end-user, the hospital & academic laboratories is expected to account for the largest share of the molecular diagnostics market in 2018 primarily on account of the large number of diagnostic tests conducted in hospitals.

In 2018, North America is expected to account for the largest share of the global molecular diagnostics market, mainly due to the high prevalence of infectious diseases and cancers, presence of a highly developed healthcare system and large number of leading national clinical laboratories, easy accessibility to technologically-advanced instruments in the region, availability of government funds, and growing applications of molecular diagnostics in genetic disorders and cancer screening.

Related Links:
MarketsandMarkets

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.